The nation of Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years because of the United States' request for sensitive biological samples.
This move was revealed after a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "skewed".
An official representative has since clarified that the United States was requesting genetic material for scientific study and profit while refused to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more dialogue to find a deal acceptable to all parties so the nation's vital HIV treatment initiative can continue.
Wider Background
This rejection follows a comparable situation in Kenya, where a high court suspended a related deal with the US following concerns were filed about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
As per statements, 16 African countries have so far signed these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information indefinitely, with no corresponding guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our country would provide the basic resources for medical research without any certainty that the end products would be accessible to our population if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were upending structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent co-operation could be structured in a way that honours the independence and dignity of both nations."
Health Experts Response
A leading public health body expressed it recognised the official position, but recommended that negotiations should continue since a large portion of the country's Aids initiatives depended on foreign aid.
"If technical issues exist, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal highlights the continuing debate between accepting much-needed international aid and protecting local interests in an ever more data-driven world.